

# company announcement

## Trading in Novo Nordisk shares by board members, executives and associated persons

**Bagsværd, Denmark, 3 May 2024** — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer</b>	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
<b>4</b>	<b>Details of the transaction(s)</b>	

a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.05</td> <td>178 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.05	178 shares		
Price(s)	Volume(s)							
DKK 900.05	178 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>	178 shares DKK 160,208.90						
e)	Date of the transaction	2024-05-02						
f)	Place of the transaction	AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD)						

<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name of the Board member/Executive/Associated Person Maziar Mike Doustdar
<b>2 Reason for the notification</b>	
a)	Position/status Executive Vice President
b)	Initial notification/Amendment Initial notification
<b>3 Details of the issuer</b>	
a)	Name Novo Nordisk A/S
b)	LEI 549300DAQ1CVT6CXN342
<b>4 Details of the transaction(s)</b>	
a)	Description of the financial instrument, type of instrument, Identification code Shares  Novo Nordisk B DK0062498333
b)	Nature of the transaction Sale of shares

c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.74</td> <td>10,128 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.74	10,128 shares		
Price(s)	Volume(s)							
DKK 900.74	10,128 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul>	10,128 shares DKK 9,122,689.30						
e)	Date of the transaction	2024-05-02						
f)	Place of the transaction	AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB)						

<b>Details of the person discharging managerial responsibilities/person closely associated</b>								
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
<b>2</b>	<b>Reason for the notification</b>							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer</b>							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>							
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.17</td> <td>2,253 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.17	2,253 shares		
Price(s)	Volume(s)							
DKK 900.17	2,253 shares							

d)	Aggregated information <ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>	2,253 shares DKK 2,028,089.70
e)	Date of the transaction	2024-05-02
f)	Place of the transaction	AQUIS EXCHANGE EUROPE

<b>Details of the person discharging managerial responsibilities/person closely associated</b>								
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
<b>2</b>	<b>Reason for the notification</b>							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer</b>							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>							
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.10</td> <td>18,153 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.10	18,153 shares		
Price(s)	Volume(s)							
DKK 900.10	18,153 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>	18,153 shares DKK 16,339,540.90						

e)	Date of the transaction	2024-05-02
f)	Place of the transaction	CBOE EUROPE - DXE ORDER BOOKS (NL)

<b>Details of the person discharging managerial responsibilities/person closely associated</b>								
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
<b>2 Reason for the notification</b>								
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3 Details of the issuer</b>								
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4 Details of the transaction(s)</b>								
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.14</td> <td>2,800 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.14	2,800 shares		
Price(s)	Volume(s)							
DKK 900.14	2,800 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul>	2,800 shares DKK 2,520,380.90						
e)	Date of the transaction	2024-05-02						
f)	Place of the transaction	TURQUOISE EUROPE						

<b>Details of the person discharging managerial responsibilities/person closely associated</b>							
a)	Name of the Board member/Executive/Associated Person Maziar Mike Doustdar						
<b>2</b>	<b>Reason for the notification</b>						
a)	Position/status Executive Vice President						
b)	Initial notification/Amendment Initial notification						
<b>3</b>	<b>Details of the issuer</b>						
a)	Name Novo Nordisk A/S						
b)	LEI 549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>						
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction Sale of shares						
c)	Price(s) and volume(s) <table border="1" data-bbox="863 1106 1362 1258"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 900.00</td> <td>10,437 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 900.00	10,437 shares		
Price(s)	Volume(s)						
DKK 900.00	10,437 shares						
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul> 10,437 shares DKK 9,393,300.00						
e)	Date of the transaction 2024-05-02						
f)	Place of the transaction UBS EUROPE SE						

<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name of the Board member/Executive/Associated Person Maziar Mike Doustdar
<b>2</b>	<b>Reason for the notification</b>

a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
<b>3</b>	<b>Details of the issuer</b>							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
<b>4</b>	<b>Details of the transaction(s)</b>							
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 912.15</td> <td>11,051 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 912.15	11,051 shares		
Price(s)	Volume(s)							
DKK 912.15	11,051 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul>	11,051 shares DKK 10,080,130.60						
e)	Date of the transaction	2024-05-02						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).*

## Contacts for further information

### Media:

**Ambre James-Brown**

+45 3079 9289

[abmo@novonordisk.com](mailto:abmo@novonordisk.com)

**Liz Skrbkova (US)**

+1 609 917 0632

[lzsk@novonordisk.com](mailto:lzsk@novonordisk.com)

**Investors:**

**Daniel Muusmann Bohsen**

+45 3075 2175

[dabo@novonordisk.com](mailto:dabo@novonordisk.com)

**Jacob Martin Wiborg Rode**

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

**David Heiberg Landsted**

+45 3077 6915

[dhel@novonordisk.com](mailto:dhel@novonordisk.com)

**Mark Joseph Root (US)**

+1 848 213 3219

[mjhr@novonordisk.com](mailto:mjhr@novonordisk.com)

**Sina Meyer**

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)